AstraZeneca Signs Solar Supply Deal with ENGIE Resources

ENGIE Resources (ENGIE), a subsidiary of ENGIE North America, announced a nine-year renewable energy supply agreement with AstraZeneca, in which the biopharmaceutical company will procure solar energy and Renewable Energy Credits (RECs) through ENGIE for its manufacturing facility in Coppell, Texas. 

The initiative underscores AstraZeneca’s commitment to sustainability and responsible environmental stewardship. 

The retail supply agreement will source the energy from the Tyson Nick Solar Project, a 114-megawatt (MW) solar generator, located in Lamar County. 

Over the life of the agreement, which runs through 2034, the project will offset roughly 94,447 metric tons of carbon dioxide—equivalent to avoiding the emissions from burning 106 million pounds of coal. 

“This joint effort with AstraZeneca exemplifies how leading organizations can align climate ambition with meaningful action,” said Anne-Laure Chassanite, CEO of ENGIE Resources, in a statement. “We’re proud to deliver renewable energy in support of AstraZeneca’s decarbonization goals—and deeply grateful to the dedicated teams across both organizations whose expertise and collaboration made this agreement possible.” 

AstraZeneca is one of ENGIE’s 19 global pharmaceutical accounts and also one of the first to have its climate targets verified by the Science-Based Targets Initiative’s Net-Zero Corporate Standard. 

Kristine Robak, Key Account Director at ENGIE Resources, added, “We are privileged to work with an organization so deeply committed to both human health and environmental sustainability. By delivering the benefits of renewable energy, we’re proud to contribute to AstraZeneca’s ambitious growth and sustainability goals as they expand their manufacturing capacity in the U.S.” 

Read more here.